Hydrazine, dihydrochloride → HCID 178428372、化合物
反応式
[Cl:1][C:2]1[S:6][C:5]([C:7]([NH:9][C:10]([NH:12][C:13]2[CH:18]=[CH:17][C:16]([N:19]3[C:23](=[O:24])[C:22]4[CH:25]=[C:26]([Cl:29])[CH:27]=[CH:28][C:21]=4[C:20]3=[O:30])=[C:15]([CH3:31])[CH:14]=2)=S)=O)=[CH:4][CH:3]=1.Cl.Cl.[NH2:34][NH2:35]>CN(C=O)C>[Cl:29][C:26]1[CH:27]=[CH:28][C:21]2[C:20](=[O:30])[N:19]([C:16]3[CH:17]=[CH:18][C:13]([NH:12][C:10]4[NH:9][C:7]([C:5]5[S:6][C:2]([Cl:1])=[CH:3][CH:4]=5)=[N:35][N:34]=4)=[CH:14][C:15]=3[CH3:31])[C:23](=[O:24])[C:22]=2[CH:25]=1参加物
4
実験手順
To a suspension of (5-chloro(2-thienyl))-N-({[4-(5-chloro-1,3-dioxobenzo[c]azolin-2-yl)-3-methylphenyl]amino}thioxomethyl)carboxamide (15 mg, 0.030 mmol) and hydrazine dihydrochloride (4 mg, 0.038 mmol) in DMF (0.3 mL) was added HgO (7 mg, 0.032 mmol). The reaction was stirred at room temp for 17 hr, and HPLC purified to give the desired product 5-chloro-2-(4-{[5-(5-chloro(2-thienyl))(4H-1,2,4-triazol-3-yl)]amino}-2-methylphenyl)benzo[c]azoline-1,3-dione (2 mg) (ES-MS (M+H)+=470, 472) and the aminoguanidine intermediate N-((1E)-2-aza-1-{[4-(5-chloro-1,3-dioxobenzo[c]azolidin-2-yl)-3-methylphenyl]amino}-2-aminovinyl)(5-chloro(2-thienyl))carboxamide (2 mg) ES-MS (M+H)+=488, 490 (2Cl).